We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.

Delisted

AVEO was delisted on the 19th of January, 2023.

61 hedge funds and large institutions have $42.3M invested in AVEO Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $41.2M → $42.3M (+$1.12M)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

10% less funds holding

Funds holding: 6861 (-7)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

54% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 26

91% less call options, than puts

Call options by funds: $7K | Put options by funds: $81K

Holders
61
Holders Change
-7
Holders Change %
-10.29%
% of All Funds
1.75%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
10
Increased
12
Reduced
26
Closed
16
Calls
$7K
Puts
$81K
Net Calls
-$74K
Net Calls Change
-$52K
Name Holding Trade Value Shares
Change
Change in
Stake
BG
1
Baupost Group
Massachusetts
$7.01M
SCM
2
Sarissa Capital Management
Connecticut
$4.7M
GPP
3
Great Point Partners
Connecticut
$4.25M -$704K -54,148 -19%
BIT
4
BlackRock Institutional Trust
California
$3.96M -$455K -34,962 -14%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.69M -$77.6K -5,965 -4%
Renaissance Technologies
6
Renaissance Technologies
New York
$2.46M +$88.5K +6,804 +5%
PAI
7
Palo Alto Investors
California
$2.2M -$297K -22,837 -16%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$1.89M -$99.4K -7,639 -7%
GIM
9
Granahan Investment Management
Massachusetts
$1.24M
DVC
10
Deer VI & Co
New York
$1.24M
FRM
11
Fore Research & Management
New York
$1.23M +$877K +67,420 New
GX
12
Greylock XI
Massachusetts
$1.07M
GCM
13
Gruss Capital Management
New York
$976K +$694K +53,325 New
Northern Trust
14
Northern Trust
Illinois
$938K -$151K -11,604 -18%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$558K -$16.5K -1,269 -4%
California Public Employees Retirement System
16
California Public Employees Retirement System
California
$501K
Bank of America
17
Bank of America
North Carolina
$428K +$301K +23,105 +8,402%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$410K -$34.1K -2,620 -10%
PP
19
Paloma Partners
Connecticut
$409K +$291K +22,344 New
TC
20
TFS Capital
Pennsylvania
$385K +$43.9K +3,374 +19%
Goldman Sachs
21
Goldman Sachs
New York
$357K -$32.9K -2,533 -11%
USAA
22
United Services Automobile Association
Texas
$325K
BFA
23
BlackRock Fund Advisors
California
$288K -$1.67M -128,030 -89%
CC
24
Cannell & Co
New York
$275K
COPPSERS
25
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$270K +$192K +14,771 New

AVEO Hedge Fund Activity: Q2 2014 in Review

61 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2014, worth a combined $42.3M — up 2.7% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AVEO and 10 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 12 added.

The largest buyer was Fore Research & Management, opening a new position worth an estimated $877K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.67M.

  • 61 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2014, down from 68 in Q1 2014.
  • Funds reported $42.3M of AVEO Pharmaceuticals, Inc. stock for Q2 2014, up 2.7% quarter-over-quarter.
  • 10 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2014 and 16 closed out, a net change of -6 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2014 was Fore Research & Management, an estimated $877K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q2 2014 was BlackRock Fund Advisors, an estimated $1.67M sold.

Based on aggregated 13F filings for Q2 2014.